MNG422
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.441
- KRAS_SIGNALING_DN+0.305
- INTERFERON_GAMMA_RESPONSE+0.289
- HEDGEHOG_SIGNALING+0.261
- PANCREAS_BETA_CELLS+0.248
- ALLOGRAFT_REJECTION+0.235
- SPERMATOGENESIS+0.199
- INFLAMMATORY_RESPONSE+0.187
- APICAL_SURFACE+0.183
- KRAS_SIGNALING_UP+0.175
Top 10 suppressed
- MYC_TARGETS_V1-0.574
- CHOLESTEROL_HOMEOSTASIS-0.463
- DNA_REPAIR-0.462
- OXIDATIVE_PHOSPHORYLATION-0.455
- G2M_CHECKPOINT-0.431
- E2F_TARGETS-0.409
- PROTEIN_SECRETION-0.396
- MYC_TARGETS_V2-0.394
- UNFOLDED_PROTEIN_RESPONSE-0.393
- ANDROGEN_RESPONSE-0.378
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ee0e68bf-7fa0-4edc-a9df-30a63c2db34a | — | — | 0.902 |
| 2 | SRR1473590 | GTEX | — | 0.885 |
| 3 | MNG1098 | — | — | 0.877 |
| 4 | SRR1313642 | GTEX | — | 0.871 |
| 5 | SRR1413454 | GTEX | — | 0.871 |
| 6 | SRR1341057 | GTEX | — | 0.867 |
| 7 | TCGA-CF-A47V-01A-11R-A23W-07 | — | — | 0.867 |
| 8 | MNG690 | — | — | 0.867 |
| 9 | SRR1337431 | GTEX | — | 0.866 |
| 10 | SRR1320916 | GTEX | — | 0.864 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.441 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.305 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.289 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.261 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.248 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.235 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.199 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.187 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.183 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.175 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.171 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.089 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.064 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.015 | Idelalisib | — uncovered |